- Democrats in House and Senate introduce new drug pricing bill
- KEI statement: 21st meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines
- Dr. Elias Zerhouni defends Sanofi/Army proposed license on Zika patents, and KEI responds
- Maryland House of Delegates passes bill on prescription drug price gouging by vote of 137 to 4
- Leaked document: March 15, 2017 Note by Switzerland on India EFTA TEPA IP Chapter
- Patients, Members of Congress Ask Chilean Government to Issue Compulsory Licenses on Prostate Cancer and HCV Drug Patents
- Leaked: Three documents from RCEP negotiations
- 14 March 2017 - Senate Finance Committee grills Robert Lighthizer (USTR nominee) on trade and IPR policies
- KEI Testifies in Maryland on Drug R&D Cost Transparency Bill (HB666/SB437)
- HHS Office of Inspector General Declines to Investigate Failure to Disclose Federal Funding in Ionis Pharmaceuticals' Spinraza
According to this GQ story, the H-Prize (HR 632, 110th Congress) passed the House today by a vote of 408 to 8.
Every two years, H-Prizes worth $1 million would be given in four categories: production, storage, distribution and utilization. One $4 million prize would be awarded for hydrogen vehicles. At the end of 10 years, a $10 million grand prize would be given for a “transformational advance in hydrogen energy technology.”
The first American regional meeting on the WHO Intergovernmental Working Group on Public Health, Innovation, and Intellectual Property (IGWG) is scheduled for June 18, 2007 in Washington, DC. This first meeting is organized by PAHO, at the request of the Bolivian Government.
More meetings and working groups are going to be organized this summer and fall in preparation for the II IGWG next November 2007.
To facilitate Latin American governments and civil society effective participation in the WHO IGWG process and their better understanding of some of the proposals, KEI has prepared a report in Spanish.
To access an electronic copy of the report, visit: http://www.keionline.org/index.php?option=com_content&task=view&id=49
Blogging the May 30, 2007 Brownbag Lunch: Discussion on New U.S. Trade Policy and Access to MedicineSubmitted by Staff on 30. May 2007 - 22:00
On May 30, KEI hosted a brown bag lunch discussion on guidelines for the new U.S. trade policy recently released by the Congressional Ways and Means Committee and the Bush Administration. The event began with brief statements by panelists Fabiana Jorge of MFJ International, Rob Weissman of Essential Action, James Love of Knowledge Ecology International, and Stephanie Burgos of Oxfam, followed by a wider discussion.
May 30, 2007, "The New US Trade Agenda and Access to Medicines"
March 16, 2007, Robin Hanson on “Why Grants Won Over Prizes in Science.”
March 15, 2007. Sakiko Fukuda-Parr presents on "The Gene Revolution: GM Crops and Unequal Development."
On 23 May 2007, the 60th World Health Assembly, the World Health Organization’s highest governing body, adopted resolution WHA60.30 on Public health, innovation and intellectual property. This resolution bolstered the work program of WHO’s Intergovernmental Working Group on Public health, innovation and intellectual property (IGWG/PHI). This is the key operative section of the resolution, and the reactions by several key persons.
Venue: 1621 Connecticut Avenue Suite 500, Washington, DC 20009
Knowledge Ecology International will host a brown bag lunch and panel discussion on the generic drug/intellectual property provisions in the guidelines for a new US trade policy recently released by the Congressional Ways and Means Committee and the Bush Administration.
The new trade document is available here:
The final text of the resolution is here:
The Gotham Prize for cancer research tests the use of prizes to encourage more openness for cancer research. According to their web site:
Peter Pitts doesn't like the KSR decision, and he also doesn’t like prizes. His recent Spectator article says:
DISTURBINGLY, SOME FOLKS ARE now advocating a “prize” system where there are no drug patents. Instead, the government would pay a drug maker a lump sum for its innovation, and then the new drug would immediately be placed in the public domain.
KEI statement on bipartisan trade agreement
14 May 2007
FMI: James Love firstname.lastname@example.org, +1.202.361.3040
On May 10, 2007, Speaker Nancy Pelosi and Ways and Means Chair Charles Rangel announced a "new bipartisan " trade package. KEI has reviewed the details of the elements of section III of the agreement, concerning "patents, IPR and access to medicine."
Monday, 30 April 2007
"The sanctioning of countries for using legitimate and important flexibilities in the TRIPS agreement brings shame to all U.S. citizens who are increasingly seen in Thailand and elsewhere as bullies and hypocrites."
On Friday, March 16, KEI organized a briefing in the U.S. Capitol on Thailand’s recent compulsory licenses on three drugs; two for HIV/AIDS (Merck’s efavirenz (Stocrin) and Abbott’s lopinavir + ritonavir (Kaletra)) and one for heart disease (Sanofi’s clopidogrel (Plavix)). The briefing was sponsored by Senator Sherrod Brown and Congressman Tom Allen. Rep. Allen’s legislative assistant Todd Stein moderated a panel that included James Love of KEI, Robert Weissman of Essential Action, Dr.